Table I.
ANCA-positive lung cancer patients.
| Author, year (Refs.) | Age (years) | Gender | ANCA-positive | Pathology | Renal impairment | IPF | Lung cancer therapy | ANCA improvement post-treatment |
|---|---|---|---|---|---|---|---|---|
| Edgar et al, 1993 (10) | 62 | M | PR3-ANCA | SQ | Present | ND | BSC | ND |
| Tatsis et al, 1999 (11) | 63 | M | PR3-ANCA | ND | ND | ND | ND | ND |
| Navarro et al, 1994 (12) | 68 | M | MPO-ANCA | AD | Present | ND | Irradiation | Present |
| Morisako et al, 2006 (13) | 57 | M | PR3-ANCA | SQ | Absent | Absent | Chemotherapy | Present |
| Present case | 70 | F | PR3-ANCA | AD | Absent | Present | Surgery | Present |
| MPO-ANCA |
ANCA, anti-neutrophil cytoplasmic antibodies; M, male; F, female; PR3, proteinase 3; MPO, myeloperoxidase; SQ, squamous cell lung cancer; AD, adenocarcinoma of the lung; ND, not described; IPF, idiopathic pulmonary fibrosis; BSC, best supportive care.